Adoptive T cell therapy works well in some blood cancers but remain less effective against solid tumors. Researchers developed T-FOLactis, a probiotic–T cell chimera that links engineered bacteria directly to T cells. In colorectal cancer models, the platform improved tumor localization, strengthened local immune coordination, and produced greater antitumor activity than conventional T cell therapy.

New research from Memorial Sloan Kettering Cancer Center (MSK) shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; reveals tumor CD19 levels may predict success of CAR T cell therapy; and finds a new targeted drug combination shows promise in early trial for small cell lung cancer.